First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI

NCT03693677 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

288

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: Irinotecan Liposomal Injection
DRUG: 5-FU/LV
DRUG: Nab-Paclitaxel
DRUG: Gemcitabine

Sponsor

Federation Francophone de Cancerologie Digestive